XenoPort Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
XenoPort Inc. - overview
Established
1999
Location
Santa Clara, CA, US
Primary Industry
Biotechnology
About
XenoPort Inc. is a biopharmaceutical company focused on developing novel therapeutics to improve the treatment of neurological diseases. It aims to enhance the quality of life for patients through innovative drug delivery systems. Founded in 1999 in Santa Clara, US, XenoPort Inc.
specializes in developing new medications for neurological conditions. The company transitioned its strategy with a focus on innovative drug delivery technologies. It has completed a PIPE funding round in June 2005, raising USD 20. 00 mn, which constitutes the total amount raised.
The company has engaged in a total of 9 deals, with its last deal occurring on June 1, 2005. It was founded by individuals who have yet to be named; however, specific details about their prior ventures are currently unavailable. XenoPort Inc. develops and commercializes promising drugs aimed at treating neurological disorders.
The company combines scientific research with advanced drug delivery systems to create therapeutics that meet unmet medical needs. Their products focus on improving patient outcomes and providing enhanced therapeutic benefits through innovative formulations. In the most recent year, 2015, XenoPort reported a revenue of USD 41. 16 mn, with an EBITDA of USD -78.
08 mn, indicating a negative earnings performance for that period. Looking forward, XenoPort Inc. plans to leverage its recent funding from the PIPE round to accelerate the development of its new drug candidates aimed at neurological conditions. The company aims to expand into new geographic markets, specifically targeting regions in North America and Europe by 2025.
The capital raised will support product development and market entry strategies to enhance its therapeutic offerings.
Current Investors
Venrock, Maverick Capital, OrbiMed Advisors
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.xenoport.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.